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High-fat diet (HFD) feeding causes insulin resistance (IR) in skeletal muscle of mice, 
which affects skeletal muscle metabolism and function. The involvement of muscle- 
specific microRNAs in the evolution of skeletal muscle IR during 4, 8, and 12 weeks in 
HFD-induced obese mice was investigated. After 4 weeks in HFD, mice were obese, 
hyperglycemic, and hyperinsulinemic; however, their muscles were responsive to insulin 
stimuli. Expressions of MyomiRs (miR-1, miR-133a, and miR-206) measured in soleus 
muscles were not different from those found in control mice. After 8 weeks of HFD feeding, 
glucose uptake was lower in skeletal muscle from obese mice compared to control mice, 
and we observed a significant decrease in miR-1a in soleus muscle when compared to 
HFD for 4 weeks. miR-1a expression continued to decay within time. After 12 weeks 
of HFD, miR-133a expression was upregulated when compared to the control group. 
Expression of miR-1a was negatively correlated with glycemia and positively correlated 
with the constant rate of plasma glucose disappearance. Pioglitazone treatment could 
not reverse decreases of miR-1a levels induced by HFD. Targets of myomiRs involved 
in insulin-growth factor (IGF)-1 pathway, such as Igf-1, Irs-1, Rheb, and follistatin, were 
reduced after 12 weeks in HFD and Mtor increased, when compared to the control or 
HFD for 4 or 8 weeks. These findings suggest for the first time that miR-1 may be a 
marker of the development of IR in skeletal muscle. Evidence was also presented that 
impairment in myomiRs expression contributes to decreased myogenesis and skeletal 
muscle growth reported in diabetes.
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inTrODUcTiOn
An imbalance between energy intake and energy expenditure can lead to obesity, which presents 
adipose tissue expansion and fat accumulation in non-adipose tissues, such as skeletal muscle, 
leading to the development of insulin resistance (IR) in this tissue (1). IR is typically found in 
type 2 diabetic subjects being characterized by impaired insulin action on adipocyte lipolysis, 
suppression of endogenous glucose production, and skeletal muscle glucose uptake. Since skeletal 
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muscle constitutes about 40% of total body weight and accounts 
for about 80% of the insulin-stimulated postprandial glucose 
utilization (2), this tissue is the major player in the develop-
ment of IR and type 2 diabetes (3). The treatment with insulin 
sensitizer can attenuate or even prevent the progressive loss of 
skeletal muscle mass and the establishment of sarcopenia in type 
2 diabetic patients (4).
The myogenic regulatory factors (MRFs) that include 
myogenin, Murf4, Myf5, and MyoD, and members of the 
MEF2 family, essentially control skeletal muscle development 
(myogenesis) process. Various extracellular stimuli and distinct 
signaling pathways modulate expression of the MRFs. However, 
the insulin-growth factor (IGF)-1/phosphatidylinositol 3-kinase 
(PI3K)/AKT/MTOR is the main signaling pathway involved 
in skeletal differentiation and growth (5). IGF-1 binds to the 
IGF-1R, a tyrosine kinase receptor, and phosphorylates insulin 
receptor substrates (IRS) that activate PI3K. PI3K activation 
generates PIP3 that targets Akt, which mediates IGF-1 anabolic 
and anti-catabolic effects due via mTOR by inactivation of Foxo3 
(6–8). Therefore, the IGF-1R signaling pathway plays a central 
role in muscle cell development.
MicroRNAs (miRNAs or miRs) are small, non-coding RNA 
molecules of ~18–24 that control gene expression (9). miRNAs 
regulate the stability and translation of conventional messenger 
RNAs by base pairing with the 3′ untranslated regions of protein-
coding transcripts. Muscle-specific miRNAs, miR-1a, miR-133a, 
and miR-206, are recognized as important regulators of skeletal 
muscle development (10). miR-1 and miR-206 promoted differ-
entiation of myoblasts through downregulation of HDAC4 and 
the p180 subunit of DNA polymerase alpha, while miR-133 pro-
moted proliferation through downregulation of serum response 
factor (SRF) in C2C12 cells (11–13). Inhibition of endogenous 
miR-1 and miR-206 by using antimiRs blocked the downregula-
tion of most targets in differentiating cells, thus indicating that 
miRNA activity and target interaction are required for muscle 
differentiation (14).
miR-133a represses IGF-1R expression and signaling pathway 
during skeletal myogenesis (15), suggesting it may be a potential 
therapeutic target in muscle diseases. On the other hand, IGF-1 
and IGF-1R are targets for miR-1a, and a feedback loop between 
miR-1 expression and IGF-1 signal transduction cascade has 
been proposed in striated muscle (16). The role of IGF-1R on 
insulin signaling has been demonstrated in mice overexpressing 
a dominant-negative IGF-1 receptor (IGF-1R) in skeletal muscle 
(MKR mice) (17). These mice showed marked IR state and 
diabetes. Therefore, miRNA expression controlling IGF-1/PI3K/
AKT pathway could well be marker of decreased myogenesis in 
soleus muscle of type 2 diabetic mice. The aim of this study was 
then to investigate the involvement of muscle-specific miRNAs 
in the evolution of skeletal muscle IR during 4, 8, and 12 weeks 
in high-fat diet (HFD)-induced obese (DIO) mice. Evidence 
was obtained that miR-1a may be an early-stage marker of IR 
evolution in skeletal muscle. Proliferation and differentiation are 
impaired in insulin resistant soleus muscles as miR-1a is consist-
ently decreased. Increased expression of miR-133a (after 12 weeks 
of HFD feeding) was associated to transcriptional repression of 
IGF-1R and PI3K/AKT pathway in skeletal muscle of DIO mice.
MaTerials anD MeThODs
animals
One hundred and eleven male wild-type C57BL/6J mice 
(Jackson Laboratory, Bar Harbor, ME, USA) were maintained 
at 12:12-h light–dark cycle, 23 ± 2°C. They received a standard 
diet (Nuvilab-Nuvital Nutrients Ltd., Curitiba, Parana, Brazil) 
and water ad libitum until they were 8-week-old. Experimental 
Animal Ethics Committee of the Institute of Biomedical Sciences, 
University of Sao Paulo, approved the experimental protocol of 
this study (165/11/CEUA).
study Design
Sixty animals from the same brooding were randomly and 
equally divided into 2 groups (total of 15 per group): fed with 
balanced diet (CD) (9% kcal fat, 15% kcal protein, and 76% kcal 
carbohydrate) or with high-fat diet (HFD) (59% kcal fat, 15% kcal 
protein, and 26% kcal carbohydrate) (18). Animals received bal-
anced (CD) or high-fat (HFD) diets for 4, 8, or 12 weeks. Next, 
we evaluated the effect of pioglitazone (35 mg/kg of b.w./day) on 
CD or HFD animals fed for 8 weeks. The animals were randomly 
divided into three groups (n = 7 per group): control diet (C), HFD 
(H), or HFD + plus pioglitazone (HP). Pioglitazone (EMS®) was 
mixed in the diet, and animals were treated for the last 2 weeks 
of the protocol. At the end of the defined period, the animals 
were fasted for 6 h and euthanized by cervical dislocation after 
ketamine intraperitoneal injection (100 mg/kg b.w.) and xylazine 
(50  mg/kg b.w.) for tissue harvesting. Soleus muscle was care-
fully dissected from the surrounding tissue, frozen in liquid 
nitrogen, and stored at −80°C until analysis being performed. 
Retroperitoneal, mesenteric, and epididymal adipose tissues were 
harvested and weighed to check adiposity level, and blood was 
collected for the determination of the metabolites. Body weight 
was determined every week and food intake every 3 days. The 
number of individual experiments was representative of at least 
three different litters. The total number of animals used in each 
experiment is indicated in the figure legends.
glucose Tolerance Test
After 4-, 8-, and 12-week feeding period, mice from all groups 
were fasted for 6 h and blood samples were collected from the 
tail vein for determination of fasting blood glucose (5 μL) and 
plasma insulin (20 μL) levels (time 0). After that, mice were given 
an intraperitoneal injection of glucose (2 g/kg b. w.) and blood 
samples were collected at 15, 30, 60, and 90  min afterwards. 
Blood glucose levels were measured using Glucose monoreagent 
Kit (Bioclin, Minas Gerais, Brazil). Insulinemia was measured by 
ELISA with EZRMI-13K kit (Millipore).
insulin Tolerance Test
The same initial procedure described above for Glucose tolerance 
test (GTT) was used. Mice received an intraperitoneal injection of 
insulin (0.75 mIU/g b.w.), and blood samples were collected at 0, 
10, 20, and 30 min postinjection. Glycemia was measured using 
blood glucose test strips and a glucometer (Accu-Chek, Roche, 
USA). Insulin sensitivity was calculated using the plasma glucose 
disappearance rate (Kitt) during 10- to 30-min period (19).
TaBle 1 | Primers’ sequences used to quantify mrna expression.
gene seq forward seq reverse
Igf-1 GTGAGCCAAAGACACACCCA ACCTCTGATTTTCCGAGTTGC
Igf-1R CTCTGTTACCTCTCCACCAT CTTCTCACACATGGGCTTCT
Irs-1 CTCAGTCCCAACCATAACCAG GAGTGTTCATAGGCGAGATGG
Rheb CGA TCC AAC CAT AGA GAA CAC AAT ATT CAT CCT GCC CCG CT
Mtor TGC CGC TGA GAG ATG ACA ATG GTT GTT AAT GCT GAT GAG GG
Rictor TCG GGG TTC GTG GTT CAT TA GTC CTG TTT TGT TCC ACT GC
Rptor ACC TGT TCA CAT CCT GCC TCA GGC CAG GGA TCT TTT CTA TC
Myod1 GCCCGCGCTCCAACTGCTCTGAT CCTACGGTGGTGCGCCCTCTGC
Myf5 TGACGGCATGCCTGAATGT GCTGGACAAGCAATCCAAGC
Fst AAAACCTACCGCAACGAATG GGTCTGATCCACCACACAAG
Fstl1 AATGGCAAGACCTACCTCAACC GTGCCCATCATAATCAACCTGG
Mstn GCAAAATTGGCTCAAACAGCC AGGGATTCAGCCCATCTTCTC
Hdac4 TGAGAGTGAGGAGGAAGAAGCG CAAATGACACAGGGATGCCAG
Igf-1, insulin-like growth factor 1; Igf-1R, insulin-like growth factor 1 receptor; Irs-1, 
insulin receptor substrate-1; Rheb, Ras homolog enriched in brain; Mtor, mechanistic 
target of rapamycin (serine/threonine kinase); Rptor, regulatory-associated protein 
of mTOR complex 1; Rictor, independent companion of MTOR complex 2; Myod1, 
myogenic differentiation1; Myf5, myogenic factor 5; Fst, follistatin; Fstl1, follistatin-like 1; 
Mstn, myostatin; Hdac4, histone deacetylase 4.
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glucose Uptake and Metabolism in 
isolated soleus Muscle
Soleus muscles from mice fed with HFD for 4–12  weeks were 
rapidly and carefully isolated and incubated as previously 
described, with minor modifications (20, 21). Intact soleus 
muscles were preincubated at 35°C in Krebs–Ringer bicarbonate 
buffer containing 5.6 mM glucose, pH 7.4, pre-gassed for 30 min 
with 95% O2/5% CO2 and agitation at 120 oscillations/min for 
30 min. Subsequently, the muscles were transferred to the same 
buffer containing 0.3 μCi/mL d-[U-14C]glucose and 0.2 μCi/mL 
2-deoxy-[2,6-3H]d-glucose and incubated under similar condi-
tions for 1 h in the absence or presence of 10 mIU/mL insulin. 
Phenylethylamine, diluted 1:1 v/v in methanol, was added into a 
separate compartment for 14CO2 adsorption. After the incuba-
tion period, the muscles were briefly washed in cold buffer, dried 
on filter paper, and frozen in liquid N2. [14C]-Glycogen synthesis 
(as estimated by d-[14C]-glucose incorporation into glycogen), 
decarboxylation of d-[14C]-glucose, and 2-deoxy-d-[2,6-3H]-
glucose uptake were measured as previously described (20).
Total rna isolation
Total RNA was extracted from mice soleus muscle using 
miRVana RNA Isolation kit (Thermo Scientific, Waltham, MA, 
USA) according to the manufacturer’s instructions. Total RNA 
concentration was measured using the NanoDrop 2000 spec-
trophotometer (Thermo Scientific, Waltham, MA, USA). Purity 
was determined by the 260/280  nm ratio, and the value of 2.0 
indicated a high purity of our samples.
Microrna expression
Relative miRNA expression was quantified by stem-loop RT-PCR 
technique described by Chen et al. (22). cDNA was synthetized 
from 10 ng total RNA extract according to the Taqman microRNA 
Assay Protocol by Life Technologies using Taqman microRNA 
Reverse Transcription kit (Thermo Scientific, Waltham, MA, 
USA) together with 50 nM TaqMan® MicroRNA Assays (Thermo 
Scientific, Waltham, MA, USA). miRNA expression was then 
performed by the Taqman Real-time PCR method using the 
cDNA 15× diluted, 2× TaqMan Universal PCR master mix, and 
miRNA assays from Life Technologies: snoRNA-202 (001232), 
hsa-miR-1 (002222), hsa-miR-133a (002246), and hsa-miR-206 
(000510). Real-time PCR was performed using ABI Prism 7500 
equipment (Thermo Scientific, Waltham, MA, USA), following 
the universal protocol of amplification: 95°C for 10 min, 40 cycles 
of 95°C for 15 s, and 60°C for 1 min. The expression of miRNA 
relative to sno-202 (housekeeping) was determined using the 
2−ΔΔCT method.
mrna expression
cDNA was synthetized from 500 ng total RNA extract using High 
Capacity cDNA Reverse Transcription Kit (Thermo Scientific) at 
25°C for 10 min, 37°C for 120 min, with a final step of 5 min at 
85°C in an Veriti Thermal Cycler (Thermo Scientific, Waltham, 
MA, USA). All PCR reactions was then performed using diluted 
(1/10) cDNA template, forward and reverse primers (200  nM 
each) and Power SYBR Green PCRMaster Mix (Thermo-Fisher). 
Real-time PCR was performed using Rotor Gene 3500 (Qiagen, 
Hilden Germany), following the universal protocol of amplifica-
tion: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 
1 min. To verify the purity of the products, a dissociation curve 
was performed after each run according to the manufacturer’s 
instructions. For the relative gene expression quantification, also 
determined by 2−ΔΔCT, 36b4 was used as reference gene, as 36b4 
expression did not vary between diets or along the time. Genes 
analyzed included IGF-1 (Igf-1) and Igf-1 receptor (Igf-1R), 
insulin receptor substrate-1 (Irs-1), Ras homolog enriched in 
brain (Rheb), mechanistic target of rapamycin (serine/threonine 
kinase) (mTOR), regulatory-associated protein of mTOR complex 
1 (Rptor), independent companion of mTOR complex 2 (Rictor), 
myogenic differentiation 1 (Myod1), myogenic factor 5 (Myf5), 
Myostatin (Mstn), Follistatin (Fst), Follistatin-like 1 (Fstl1), and 
histone deacetylase 4 (HDAC4). Primers’ sequences are shown 
in Table 1.
Bioinformatic analysis
MyomiRs target prediction was performed using DIANA-
microT-CDS algorithm v5.0 (23, 24). A score threshold of 0.7 was 
set for searches of miRNA recognition elements (MRE) located 
in both 3′UTR and CDS regions of mRNAs. Then, we used the 
DIANA-miRPath v2.0, an online software suite dedicated to the 
assessment of miRNA regulatory roles and the identification of 
controlled pathways. (25).
statistical analysis
The results are presented as mean ± SEM and were analyzed by 
using one-, two-, or three-way ANOVA, followed by Bonferroni 
posttest. For two- and three-way ANOVA, when there was no 
interaction between the two or three factors, respectively, the 
factors or the interaction between two factors were considered 
separately, and the all pairwise multiple comparison test Holm–
Sidak was performed. Spearman’s or Pearson’s rank correlation 
coefficient was used to find which variables were correlated. 
TaBle 2 | adipose tissue weight, glucose, and insulin tolerance tests in mice fed either control or high-fat diets for 4, 8, or 12 weeks.
Measurements 4 weeks 8 weeks 12 weeks Time  
and diet
Time Diet
cD (15) hFD (14) cD (12) hFD (15) cD (13) hFD (15) p* p p
Initial body weight (g) 21.5 ± 1.5 22.3 ± 1.5 22.3 ± 0.13 22.0 ± 1.2 22.8 ± 1.7 22.3 ± 2.0 >0.05 >0.05 >0.05
Final body weight (g) 22.8 ± 1.2 27.2 ± 2.3a 23.6 ± 1.2 32.1 ± 3.2ab 24.1 ± 1.6 36.1 ± 4.7abc <0.05 – –
Body weight gain (final−initital) (g) 1.3 ± 0.9 4.9 ± 2.0a 1.3 ± 1.2 10.2 ± 3.11ab 0.73 ± 1.83 14.0 ± 3.3abc <0.05 – –
Retroperitoneal fat pad (g) 0.11 ± 0.02 0.30 ± 0.10a 0.13 ± 0.04 0.55 ± 0.16ab 0.13 ± 0.03 0.60 ± 0.14ab <0.05 – –
Epidydimal fat pad (g) 0.37 ± 0.04 0.71 ± 0.25a 0.39 ± 0.08 1.31 ± 0.33ab 0.38 ± 0.09 1.67 ± 0.41abc <0.05 – –
Mesenteric fat pad (g) 0.30 ± 0.08 0.44 ± 0.12 0.25 ± 0.11 0.45 ± 0.13 0.21 ± 0.10 0.48 ± 0.15 >0.05 >0.05 <0.05
Gastrocnemius weight (mg) 127 ± 10 144 ± 13 139 ± 12 150 ± 13 141 ± 13 156 ± 12 >0.05 <0.05 <0.05
Relative gastrocnemius 
weight (mg/b.w.) 
5.6 ± 0.4 5.4 ± 0.4 5.9 ± 0.5 4.7 ± 0.3ab 5.9 ± 0.6 4.3 ± 0.5ab <0.05 – –
Liver weight (g) 0.92 ± 0.14 0.87 ± 0.09 0.92 ± 0.09 1.01 ± 0.12b 0.91 ± 0.08 1.08 ± 0.18ab <0.05 – –
Liver TG content (g) 1.01 ± 0.58 0.73 ± 0.16 1.05 ± 0.84 1.82 ± 1.15 4.97 ± 2.38 7.36 ± 3.57 >0.05 <0.05 >0.05
Steatosis score (0–3) 0 (0–1) 0 (0–1) 0 (0–1) 1 (0–1)a 0 (0–1) 1 (0–2)ab <0.05 – –
Fasting glycemia (mg/dL) 136 ± 24 177 ± 31 144 ± 9 188 ± 31 126 ± 20 168 ± 26 >0.05 >0.05 <0.05
Fasting insulin levels (ng/
mL)
0.41 ± 0.09 0.99 ± 0.48 0.30 ± 0.09 1.24 ± 0.64 0.69 ± 0.54 1.83 ± 1.03 >0.05 <0.05 <0.05
Kitt (%/min) 5.3 ± 0.51 4.26 ± 0.71 4.99 ± 0.66 3.38 ± 0.98 4.66 ± 0.88 2.84 ± 0.74 >0.05 <0.05 <0.05
HOMA-IR 2.9 ± 1.6 7.7 ± 3.5 1.7 ± 0.9 10.8 ± 6.4 2.4 ± 1.7 16.0 ± 13.1 >0.05 >0.05 <0.05
HOMA-β 50.3 ± 18.7 58.5 ± 28.7 28.3 ± 11.8 87.6 ± 41.4ab 44.6 ± 24.0 122.7 ± 35.1abc <0.05 - -
AUC GTT 15532 ± 3078 24518 ± 4765 16770 ± 2651 28764 ± 4920 15616 ± 2429 26538 ± 6829 >0.05 >0.05 <0.05
AUC GTT, area under curve of glucose tolerance test; Kitt, constant for glycemia decay obtained from insulin tolerance test; HOMA, homeostasis model assessment; IR, insulin 
resistance; β, beta pancreatic cells. Data are expressed as mean ± SD, except for steatosis score, which is presented as medians with range (0: <5%; 1: 5–33%; 2: 33–66%; 3: 
>66% of hepatocytes with lipids). In bold, significant values of time or diet. In parenthesis, the total number of mice studied.
*p for interaction of time and diet as indicated by two-way ANOVA.
a,b,cp < 0.05 as indicated by Bonferroni posttest vs. control dieta; 4 weeks of HFDb; and 8 weeks of HFDc.
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Then, a multivariate linear regression analysis was used to evalu-
ate which variables could independently predict increments in 
glycemia. Variables that presented multicollinearity among the 
independent variables were excluded. Statistical tests were per-
formed using the Sigma Stat version 3.5. Level of significance was 
set to p < 0.05.
resUlTs
Body Weight gain, Weight of adipose 
Depots, and glucose and insulin Tolerance 
Tests
Mice fed with HFD showed augment of body weight gain, weights 
of adipose depots, fasting insulin levels, HOMA-IR, constant of 
glucose disapearance (Kitt), the area under the curve (AUC) 
of GTT, and so IR and glucose intolerance conditions were 
established already after 4 weeks (Table  2; Figures  1A,B). As 
expected, a prolonged time on HFD worsened the obesity and 
IR. Interestingly, after 8 and 12  weeks of HFD, gastrocnemius 
muscle weight was lower than that of CD mice (Table 2). We also 
noted a progressive increase in liver weight with time, which was 
a result of ectopic triglyceride (TG) accumulation as indicated by 
measurement of steatosis score, calculated after histopathological 
examination, and TG content (Table 2).
Glucose metabolism and insulin responsiveness were 
investigated in soleus muscle that is rich in oxidative (I and 
IIa type) fibers (26) (Figures  1C–L). Insulin stimulated 2-DG 
uptake (Figure 1E), glycogen synthesis (Figure 1H), and glucose 
oxidation (Figure 1L) in soleus muscle of mice. Mice fed with 
HFD presented lowered 2-DG uptake (Figure 1E) and glycogen 
synthesis (Figure 1H) induced by insulin and glycogen oxida-
tion (Figure 1J). After 8 weeks of HFD, soleus muscle presented 
significant decrease in glucose uptake (Figure 1D) compared to 
control-fed mice. After 12 weeks of feeding CD or HFD (20 weeks 
of age), soleus muscles were not responsive to insulin stimulus 
for glycogen synthesis anymore, and 20-week-old animals were 
less responsive to insulin-stimulated glycogen synthesis than 
12-week-old or 16-week-old animals (fed for 4 or 8 weeks with 
CD or HFD, respectively) (Figure  1G). As well as this, soleus 
muscles from 20-week-old mice presented lower glucose oxida-
tion, independently of the diet received (12 weeks of CD or HFD) 
(Figure 1K).
mirnas expression in the soleus Muscle 
of Mice Fed hFD for 4, 8, or 12 Weeks
Two-way ANOVA revealed an interaction of period of time stud-
ied and diet only in miR-133a expression (Figure 2A). Different 
from control mice, animals on HFD showed an increase by 
twofold of miR-133a expression in soleus muscles after 12 weeks 
(Figure 2A). miR-1a expression was different along the time (4 
vs. 8 or 12 weeks) and between control and HFD (Figures 2B–D), 
and miR-206 expression was different along the time (4 vs. 8 or 
12 weeks, and 8 vs. 12 weeks, p < 0.05) (Figures 2E,F).
expression of mrnas in soleus Muscle of 
Mice fed hFD for 4, 8, and 12 Weeks
Due to the fact that myomiRs are strongly associated to myogene-
sis and myomiR targets are involved in IGF-1/PI3K/AKT/MTOR 
FigUre 1 | insulin sensitivity and glucose tolerance in control- or hFD-fed c57Bl/6J mice. (a) Glycemic curves obtained from GTT after injection of 
glucose (2 g/kg/b.w.); (B) glycemic curves obtained from ITT after injection of insulin (0.75 mIU/g b.w.); (c,F,i) glucose metabolism in soleus muscle of control- and 
HFD-fed animals after stimulation (+) or not (−) with insulin 10 mIU/mL after 4-, 8-, and 12-week feeding period. (c–e): glucose uptake average for each group in 
the absence/presence of insulin (c), interaction between insulin and diet (D), and interaction between time and diet (e). (F–h): glycogen synthesis average for each 
group in the absence or presence of insulin (F), interaction between insulin and time (g), and interaction between insulin and diet (h). (i–l): glucose oxidation 
average for each group in the presence and absence of insulin (i) and effect of diet (J), time (K), and insulin (l) separately on glucose oxidation. a,b and *p < 0.05 
as indicated by three-way ANOVA followed by all pairwise multiple comparison test Holm–Sidak for interaction between two factors or effect of just one factor. (a,b) 
compared to 4 or 8 weeks, respectively. CD, control-fed mice; HFD, high-fat diet-fed mice.
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pathway, we postulated that decreases in miR-1a and increases in 
miR-133a levels could be associated with decreased myogenesis 
in skeletal muscles of insulin-resistant mice. Interaction between 
period of time studied and diet was found in mRNA expression 
of Igf-1, Irs-1, Rheb, mTOR, and Rictor (Mtorc2). HFD-fed mice 
showed a significant reduction on expression of Igf-1, Igf-1R, 
and Rheb after 12 weeks when compared to the paired control 
group (Figure 3A). This pattern of expression is consistent with 
an increase of miR-133a levels (Figure 2A), which has Igf-1R as 
target (15). Irs-1 level was significantly lowered in soleus muscles 
in 8-week HFD-fed animals as compared with paired control 
and 4-week HFD mice. mTOR level was upregulated in soleus 
muscles of 12-week-fed HFD mice, which is consistent with 
Rheb inhibition. Mtorc1 (Rptor) was higher expressed in soleus 
muscle of HFD animals (CD: 1.2 ±  0.09 vs. HFD: 1.5 ±  0.12, 
p < 0.05), but it was not different from control after 12 weeks 
of HFD. This is in agreement with Mtorc1 upregulation in 
obesity (27). Levels of Rictor (mTorc2) increased only at 8 weeks 
of HFD when compared to control, and then is reduced after 
12 weeks of HFD (Figure 3A). Mtorc2 phosphorylates AKT at 
residue Ser-473, activating it, and reduction in Rictor expression 
inhibits AKT (28). These results suggest IGF-1 anabolic effect is 
reduced in 12-week HFD mice. In order to confirm a decreased 
myogenesis in soleus muscle, we have measured some myogenic 
response factors. Fst, Mstn, and Hdac4 expression showed an 
interaction between time and diet. Myostatin (Mstn) was lowered 
in 4-week HFD-fed animals as compared to the control group. 
Concurrently, its inhibitor Follistatin (Fst) was upregulated in 
soleus muscles of mice fed HFD for 4 weeks (Figure 3B). Hdac4, 
a transcription repressor, and target of miR-1 and miR-206, was 
increased in soleus muscle of mice in HFD for 12 weeks com-
pared to control and with 4 and 8 weeks of HFD (Figure 3B). 
FigUre 2 | Time-course of muscle-specific micrornas mir-133a (a), mir-1a (B), and mir-206 (e) expression in soleus muscle of high-fat diet (hFD) 
and control diet (cD)-fed mice. Total RNA was extracted from soleus muscle of HFD- and CD-fed mice, and 10 ng was used for stem-loop reverse transcription. 
RT products were used for TaqMan real-time PCR. SnoRNA-202 was used for normalization. *p < 0.05 as indicated by two-way ANOVA followed by Bonferroni 
posttest; (c,D) effect of diet and time separately on miR-1a expression, respectively, *p < 0.05 as indicated by one-way ANOVA followed by Holm–Sidak method; 
(F) effect of the time on miR-206 expression, *p < 0.05 as indicated by one-way ANOVA followed by Holm–Sidak method.
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Expressions of Myf5 was significantly reduced by HFD feeding 
(CD: 0.69 ±  0.08 vs. HFD: 0.39 ±  0.05, p <  0.05) and by the 
time (4 weeks: 0.81 ± 0.11 vs. 12 weeks: 0.41 ± 0.06, p < 0.05), 
independently. These observations are in agreement with the 
loss of skeletal muscle mass observed in sarcopenia, which is 
accelerated by diabetes. Interestingly, relative to body weight, a 
progressive loss of skeletal muscle was observed in HFD mice, 
especially at 8- and 12-weeks times, which was not observed in 
control (Table 2).
lower expression of mir-1 is correlated 
with insulin resistance in DiO Mice but is 
not restored by Pioglitazone Treatment
A significant positive correlation between miR-1 and miR-206 
expression was found in all individuals (r =  0.70, p <  0.05). 
A negative correlation between miR-1 and fasting glycemia 
(r = −0.43, p <  0.05) and body weight (r = −0.48, p <  0.05) 
and a positive correlation between miR-1 and Kitt (r =  0.41, 
p  <  0.05) were also found (Figure  4). This correlation was 
not observed on miR-206 levels (data not shown). When we 
separated control from obese, we found a strong positive cor-
relation between plasma insulin concentration and miR-1 levels 
(r = 0.82, p < 0.05) and miR-1 expression and mTOR mRNA 
levels (r =  0.51, p <  0.05) in soleus muscles of control diet-
fed mice. Interestingly, in C2C12 differentiating cells, Mtor is 
important for upregulation of MyoD, which in turn upregulates 
miR-1 (29). Mtor and miR-1 correlation was lost, but Kitt and 
Fst mRNA levels were positively correlated and body weight and 
Myod mRNA levels negatively correlated with miR-1 levels in 
soleus muscles (Figure 4).
Finally, we performed a multiple linear regression analysis, 
to understand which variables were independently associated 
to glycemia in our DIO model. As this model is very sensi-
tive to body weight, this variable was used as an independent 
variable. Body weight was correlated with glycemia, liver weight, 
Steatosis score, Rheb and Igf-1 expression, and gastrocnemius 
weight (data not shown). Other variables used in the model 
were miR-1a (correlated to glycemia) and miR-206 (correlated 
to miR-1a levels), and miR-133a, Rheb, Igf-1, Mtor, and Mstn 
mRNAs expression, and gastrocnemius weight, because they 
were significantly associated to IR progression. The model with 
an adjusted R2 = 0.734 resulted in the following variables appear-
ing to account for the ability to predict glycemia (p < 0.05): body 
weight, gastrocnemius weight, Mtor, Rheb, Mstn, miR-1a, and 
miR-206 expression.
FigUre 3 | Time-course of mrnas expression involved in igF-1/Pi3K/aKT/MTOr pathway (a) and with myogenesis (B) in soleus muscle of high-fat 
diet (hFD)- and control diet (cD)-fed mice. Total RNA was extracted from soleus muscle of HFD- and CD-fed mice, and 500 ng was used for reverse 
transcription. RT products were used for SyBR green real-time PCR. 36B4 gene was used for normalization. *p < 0.05 as indicated by two-way ANOVA followed by 
all pairwise multiple comparison procedure: Holm–Sidak method. Only significant values for interactions of time and diet are shown. For separate analysis of time 
and diet, please see the Section “Results.”
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To evaluate if treatment with an insulin sensitizer, such as 
pioglitazone, could restore muscle-specific miRNAs, we treated 
DIO mice with pioglitazone 35  mg/kg/day. Pioglitazone treat-
ment of HFD for 15 days partially restored insulin sensitivity as 
measured by the Kitt (C: 6.3 ± 0.7%/min vs. H: 2.7 ± 0.3%/min vs. 
HP: 4.8 ± 0.6%/min, p < 0.05). Regardless of improving insulin 
sensitivity, pioglitazone could not restore miR-1a, miR-133a, or 
miR-206 levels in soleus muscles (Figure 5).
DiscUssiOn
Muscle-specific miRNAs (e.g., miR-1a, miR-133a, and miR-206) 
have been reported to play critical role in myogenesis. MyomiRs 
have been shown to target IGF-1 signaling pathway, which is 
associated with insulin response in skeletal myocytes. Evidence 
is presented herein that miRNAs may be markers of the evolution 
of insulin resistance in soleus muscle.
Glucose intolerance and IR in mice exposed to an HFD devel-
ops within 3 days on an HFD but does not worsen significantly, 
even after 12 weeks on an HFD (30). Regardless of hyperinsuline-
mia, IR, and glucose intolerance observed in 4 weeks of HFD, the 
onset of IR in skeletal muscle of DIO mice was observed only after 
8 weeks with impact on skeletal muscle mass loss. In line with 
unaltered glucose metabolism in soleus muscles after 4 weeks in 
HFD, a recent work has shown the maintenance of muscle insulin 
sensitivity in mice fed with HFD for 3 weeks (31). After 5 weeks in 
HFD, an impaired insulin-mediated glucose uptake was observed 
in DIO mice (32).
Mattson’s group (33) showed that control laboratory mice 
are sedentary, glucose intolerant, and obese as compared to wild 
mice. Researchers have shown reducing daily food intake or 
providing exercise training results in increased plasma adiponec-
tin and reduced insulin levels (34) and increases whole body 
insulin sensitivity mainly related to raised skeletal muscle glucose 
FigUre 4 | mir-1 is correlated with metabolic parameters in mice. (a) Samples from control and obese mice: significant correlations between miR-1, Kitt, 
and glycemia are shown; (B) only control mice samples were used for this analysis: insulin plasma levels and mTor mRNA significantly correlated with miR-1a levels; 
and (c) only obese mice were used in these analyses: significant correlations were found between miR-1a and Kitt, MyoD and Fst mRNA. Spearman’s correlation 
analysis was used to determine the correlation. Gray dot: 4 weeks, open circle: 8 weeks, and black dot: 12 weeks.
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FigUre 5 | effect of pioglitazone 35 mg/kg/day on muscle-specific micrornas expression in soleus muscles of hFD-fed mice. Animals were fed for 
8 weeks with high-fat diet and treated with pioglitazone for 2 weeks. Total RNA was extracted from soleus muscles for microRNA expression. *p < 0.05 as indicated 
by one-way ANOVA followed by Holm–Sidak method.
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oxidation (35) in ad  libitum fed and sedentary rodents. Thus, 
rodents housed under standard laboratory conditions are rela-
tively insulin resistant (33), as observed herein after the 12-week 
period. Corroborating with these results, using a mice-to-human 
age map (36), for non-insulin dependent diabetes mellitus, the 
mouse age of 140 days (20-week-old) would be mapped to the 
55-year-old in humans (r2 =  0.647); a high risk age for type 2 
diabetes mellitus (37, 38).
Impaired insulin action or release impacts negatively on 
skeletal muscle health as this tissue is the largest body site for 
glucose consumption. Diabetic myopathy, characterized by 
reduced physical capacity, strength, and skeletal muscle mass is a 
common complication of diabetes. Our data show a reduction in 
skeletal muscle mass, specifically gastrocnemius muscle, exactly 
at the same time IR in skeletal muscle is established. A recent 
work on skeletal muscle regeneration demonstrated a delayed 
muscle repair process in DIO mice and an impaired activation of 
muscle satellite cells (39), which might contribute to sarcopenia 
related to type 2 diabetes.
There is cumulative evidence that miRNAs are associated with 
the development of diabetic complications (40). We evaluated the 
evolution of the expression of miR-1a, miR-133, and miR-206 in 
mice fed a HFD for 4, 8, or 12  weeks. A reduction in miR-1a 
expression in soleus of HFD-fed animals was observed, and, 
particularly, miR-133a was upregulated after 12  weeks of HFD 
compared to control mice. Interestingly, miR-1a expression, 
together with other variables, appears to account for fasting 
glycemia increments. Others have also shown a role of myomiRs 
in IR. Downregulation of miR-1, miR-206, and miR-133 levels 
has been reported in white adipocytes (41) and in gastrocnemius 
muscle (42) of DIO mice and in vastus lateralis (43) and plasma 
(44, 45) of type 2 diabetic patients.
Treatment with pioglitazone did not restore miRNAs expres-
sion in soleus muscle of HFD mice, despite the fact it increased 
insulin sensitivity. Not surprisingly, treatment with pioglitazone 
did not restore microRNAs expression in soleus muscle of HFD 
mice, despite the fact it increased insulin sensitivity. Agonists of 
peroxisome proliferator-activated receptor γ (PPARγ), such as 
pioglitazone, has shown to significantly inhibit myotube forma-
tion of C2C12 myoblasts, whereas GW9662, a PPARγ antagonist, 
increased the number and length of myotubes (46). In addition, 
the in vitro ectopic expression of PPARγ in C2C12 cells induced 
their transdifferentiation into adipocytes (47). This may be the 
reason pioglitazone (3  mg/kg) treatment of rats for 8  weeks 
induced fat accumulation in oxidative and glycolytic skeletal 
muscles (48).
miR-1a, miR-133a, and miR-206 are specifically induced 
during myogenesis (49) and myogenic transcription factors, 
such as MyoD, Myf5, Myog, and Mef2, mediate upregulation of 
these miRNAs (49–51). Alternatively, miRNAs repress proteins 
important for muscle differentiation such as HDAC4, a negative 
regulator of myogenesis, myostatin, and follistatin-like 1 (52, 53). 
Consistent with miR-1a reduction, soleus muscle from HFD-fed 
mice showed lower expression of Myf5, a transcription factor 
essential for miR-1a upregulation compared to control-fed mice 
(51). Zhou et al. (54) also found lower expression of β-catenin-
related genes, Myf5, MyoD, and Irs-1, in skeletal muscle of DIO 
rats when compared with rats fed with a HFD that remained lean 
(obesity-resistant). The authors of this study postulated a cross 
talk between Wnt/β-catenin, and insulin sensitivity markers exists 
FigUre 6 | evolution of the changes in skeletal muscle and insulin sensitivity in diet-induced obese mice. The figure illustrates the time each parameter 
first appear.
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